CureVac Shareholders Approve Landmark BioNTech Acquisition

CureVac investors have officially cleared the path for the company’s acquisition by vaccine developer BioNTech, bringing months of anticipation to a decisive conclusion. During an extraordinary general meeting held this week, shareholders overwhelmingly endorsed the merger agreement, setting the stage for the Tübingen-based firm’s integration into its Mainz-based counterpart.

Shareholder Support Reaches Near-Unanimous Levels

The voting results demonstrated exceptional investor consensus. An impressive 99.16 percent of participating shareholders approved the public exchange offer, while the legal merger required for structural integration into BioNTech received near-unanimous backing at 99.95 percent. These decisive outcomes remove the primary corporate governance obstacles, effectively finalizing the transaction.

Critical Deadline Approaches for Current Investors

With regulatory and shareholder approvals secured, attention now turns to practical implementation. Current CureVac shareholders face an important timeline consideration. The companies have issued a strong recommendation to tender shares by December 2, 2025, at 6:00 PM ET.

Although the formal offer period extends until the morning of December 3, adhering to the earlier suggested date ensures seamless processing through brokerage platforms. Investors who miss these deadlines risk complications during the share conversion process and potential delays in receiving BioNTech equity.

Should investors sell immediately? Or is it worth buying CureVac?

Quarterly Performance Defies Expectations

Coinciding with the acquisition developments, CureVac disclosed third-quarter financial results that countered negative market speculation. The company maintained profitability despite revenue declining to €54.1 million, a figure affected by substantial one-time payments in the prior-year period.

Notably, CureVac recorded a surprising net profit of €273.2 million, translating to earnings per share of €1.21. These robust earnings figures have generated limited market reaction, as share price movements are now predominantly influenced by arbitrage activity and the predetermined exchange ratios rather than fundamental performance.

Investment Implications

The shareholder vote effectively marks the conclusion of CureVac’s independent operations. For existing investors, fundamental analysis has become largely irrelevant, with technical execution now taking priority. Shareholders must complete the administrative process within the specified timeframe to ensure successful conversion to BioNTech stock.

The company’s equity, which has appreciated more than 34 percent since January, continues to trade primarily on deal mechanics rather than traditional valuation metrics, signaling the final chapter for CureVac as a standalone publicly-traded entity.